ArticleMetabolic brain disease2026
Quassin ameliorates acute cerebral infarction with attenuation of NF-κB signaling and neuroinflammation.
Article in Metabolic brain disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Acute cerebral infarction is a severe cerebrovascular disease characterized by neuronal injury, oxidative stress, and neuroinflammatory activation. Quassin is a bioactive quassinoid isolated from Quassia amara with reported antioxidant and anti-inflammatory activities; however, its protective effects against cerebral ischemic injury and the underlying mechanisms remain to be further clarified. In this study, middle cerebral artery occlusion/reperfusion rat models and oxygen-glucose deprivation/reoxygenation models in bEnd.3 brain microvascular endothelial cells were established to evaluate the neuroprotective effects of Quassin. Neurological deficit scoring and hematoxylin-eosin staining were used to assess neurological dysfunction and brain histopathological injury. Cell viability was detected using the Cell Counting Kit-8 assay. Inflammatory cytokines were measured by quantitative polymerase chain reaction and enzyme-linked immunosorbent assay, intracellular reactive oxygen species were detected by DCFH-DA staining and flow cytometry, and nuclear factor kappa B pathway activation was analyzed by immunohistochemistry and Western blotting. Quassin markedly improved neurological deficits, alleviated brain histopathological damage, and restored cell viability after ischemic injury. Moreover, quassin reduced reactive oxygen species accumulation and decreased the expression of interleukin-1 beta, interleukin-6, tumor necrosis factor alpha, and inducible nitric oxide synthase. At the molecular level, quassin reduced the phosphorylation of IκBα and p65, consistent with attenuated NF-κB signaling activation. The nuclear factor kappa B inhibitor pyrrolidine dithiocarbamate further supported the involvement of this pathway. These findings suggest that the protective effects of quassin against cerebral ischemic injury are associated with reduced oxidative stress, neuroinflammation, and NF-κB signaling activation.
Indexed as
Identifiers
42891903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.